Maker of Budweiser is partnering with medical cannabis company Tilray in a $100m deal to research cannabis-infused drinks for Canadian market
- Anheuser-Busch InBev and Tilray Inc. said each company would invest $50m in a project to study non-alcoholic drinks containing cannabidiol, or CBD, and THC
- CBD is claimed to have calming and healing effects and is non-psychoactive
- Tetrahydrocannabinol (THC) is the psychoactive compound found in marijuana
- AB InBev said it will participate through subsidiary Labatt Breweries of Canada
- North American consumer spending on legal cannabis is expected to grow from $9.2 billion in 2017 to $47.3 billion in 2027
The maker of Budweiser is partnering with medical cannabis company Tilray in a $100 million deal to research cannabis-infused drinks for the Canadian market.
The alliance announced on Wednesday is the latest foray by a major beer company into the cannabis business in Canada, which legalized recreational marijuana in October.
Anheuser-Busch InBev and Tilray Inc. said each would invest $50 million in the project to study non-alcoholic drinks containing cannabidiol, or CBD, which some claim has calming and healing effects, and Tetrahydrocannabinol, or THC, the cannabis compound known for its psychoactive effects.
Tilray had announced a day earlier that a subsidiary struck a deal with pharmaceutical company Sandoz AG to jointly operate in jurisdictions where cannabis is, or will be, approved for medical purposes.
Tilray’s shares jumped 15 per cent following news of the deal with AB InBev. Shares of AB InBev were little changed.
Belgium-based Anheuser-Busch InBev, the maker of Budweiser, announced on Wednesday that it’s partnering with medical cannabis company Tilray in a $100 million deal to research cannabis-infused drinks for the Canadian market, through its Labatt Breweries of Canada subsidiary. Budweiser beer cans are shown on ice in this file photo taken at a concession stand at McKechnie Field in Bradenton, Florida on March 5, 2015
Belgium-based AB InBev, the owner of more than 500 beer brands including Budweiser and Stella Artois, said it will participate in the project through its subsidiary Labatt Breweries of Canada.
‘Labatt is committed to staying ahead of emerging consumer trends,’ President Kyle Norrington said.
British Columbia-based Tilray has products available in 12 countries and operations in Australia, New Zealand, Canada, Germany, Latin America and Portugal.
Canada has emerged as a world leader in the cannabis industry, which is surging as legalization also expands in the United States.
North American consumer spending on legal cannabis is expected to grow from $9.2 billion in 2017 to $47.3 billion in 2027, according to Arcview Market Research, a cannabis-focused investment firm. A file photo of marijuana plants grown at MedPharm Research warehouse in Denver, Colorado on December 7 is shown
North American consumer spending on legal cannabis is expected to grow from $9.2 billion in 2017 to $47.3 billion in 2027, according to Arcview Market Research, a cannabis-focused investment firm.
Earlier this month, Marlboro maker Altria Group Inc. invested $1.8 billion for a 45 percent stake in Cronos Group, a Canadian medical and recreational marijuana provider.
In August, wine, liquor and beer company Constellation Brands announced a $4 billion investment in Canadian pot producer Canopy Growth Corp.
Coca-Cola, Pepsi and Guinness brewer Diageo have said they are closely watching the market for cannabis as it evolves.